Search - tctmd.com

Displaying 381 - 397 of 397

Sort: Relevancy | Date

News Daily News

Nonaccess Site Bleeding After PCI Strongly Tied to Long-term Mortality

March 08, 2011

News Daily News

High-Dose Maintenance Clopidogrel Lowers Platelet Reactivity, Other Risk Factors

February 06, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

January 04, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

January 04, 2011

CME

The Role of Atrial Shunts in the Treatment of HFpEF

CME

State of the Art: Creating Left-to-Right Shunts as a Treatment for Chronic Heart Failure

CME

Managing the Growing Epidemic of HF: The Potential Role of Shunts

CME

Balancing Ischemic and Bleeding Risk with Antiplatelet Therapy: Personalizing Treatment to Optimize Outcomes

CME

Latest Data in Renal Denervation

CME

Aspirin for the Interventionalist: More Than Meets the Eye

CME

Everyday Antiplatelet Decisions: Making the Right Choices

CME

Transcatheter Mitral Valve Repair in Heart Failure: Integrating New Randomized Trial Data Into Clinical Practice

CME

Changing Course with Anticoagulation in Secondary Prevention of CAD

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Advertisement

Nonaccess Site Bleeding After PCI Strongly Tied to Long-term Mortality

High-Dose Maintenance Clopidogrel Lowers Platelet Reactivity, Other Risk Factors

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

The Role of Atrial Shunts in the Treatment of HFpEF

State of the Art: Creating Left-to-Right Shunts as a Treatment for Chronic Heart Failure

Managing the Growing Epidemic of HF: The Potential Role of Shunts

Balancing Ischemic and Bleeding Risk with Antiplatelet Therapy: Personalizing Treatment to Optimize Outcomes

Latest Data in Renal Denervation

Aspirin for the Interventionalist: More Than Meets the Eye

Everyday Antiplatelet Decisions: Making the Right Choices

Transcatheter Mitral Valve Repair in Heart Failure: Integrating New Randomized Trial Data Into Clinical Practice

Changing Course with Anticoagulation in Secondary Prevention of CAD

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content